Notice of R ferenc s Cited

Application/Control No.
09/676,340

Examiner

Applicant(s)/Patent Under Reexamination SUBJECK ET AL.

Examiner Art Unit Stephen L. Rawlings, Ph.D. 1642

Page 1 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-5,747,332-A	05-1998	Wallen et al.	435/272
	В	US-6,156,302-A	12-2000	Srivastava	424/93.1
	С	US-6,017,540-A	01-2000	Srivastava et al.	424/193.1
	D	US-6,403,095-B1	06-2002	Srivastava et al.	424/193.1
	Е	US-6,162,436-A	12-2000	Srivastava	424/193.1
	F	US-5,981,706-A	11-1999	Wallen et al.	530/350
	G	US-6,066,716-A	05-2000	Wallen et al.	530/350
	Н	US-6,331,299-B1	12-2001	Rothman et al.	424/93.21
	ı	US-6,322,790-B1	11-2001	Srivastava	424/193.1
	J	US-5,891,432-A	04-1999	Ноо	424/93.21
	К	US-6,187,312-B1	02-2001	Srivastava	424/193.1
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	P					
	α					
	R			•		
	s					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Wang, X-Y, et al, 2001, Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity, Journal of Immunology, Vol. 165, pp. 490-497.
	V	Chen, C-H, et al, 2000, Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene, Cancer Research, Vol. 60, pp. 1035-1042.
	w	Moroi, Y, et al, 2000, Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70, Proceedings of the National Academy of Sciences USA, Vol. 97, No. 7, pp. 3485-3490.
	х	Janetzki, S, et al, 2000, Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study, International Journal of Cancer, Vol. 88, pp. 232-238.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Not The State of Not

Notice of References Cited

Notice of Referenc s Cit d

Application/Control No. 09/676,340	Applicant(s)/Pater Reexamination SUBJECK ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1642	Page 2 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	κ	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N			•		
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	υ	Tamura, Y, et al, 1997, Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations, Science, Vol. 278, pp. 117-120.
	v	Disis, ML, et al, 1999, Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clinical Cancer Research, Vol. 5, pp. 1289-1297.
	w	Srivastava, PK, 1997, Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens, Methods: A Companion to Methods in Enzymology, Vol. 12, pp. 165-171.
	х	Manjili, MH, et al, 2002, Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110, Cancer Research, Vol. 62, pp. 1737-1742.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

SR 7/8/02 Notic of References Cited

Notice of R ferenc s Cited

Application/Control No.

O9/676,340

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under
Reexamination
SUBJECK ET AL.

Art Unit
Page 3 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-		·	
	Ε	US-			
	F	US-			
	G	US-			
	Ι	US-			
	_	US-			
	J	US-			
	κ	US-			
	L	US-	_		
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Li, Z, 1997, Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines, Seminars in Immunology, Vol. 9, pp. 315-322.
	v	Blachere, NE, et al 1993, Heat shock protein vaccines against cancer, Journal of Immunotherapy, Vol. 14, No. 4, pp. 352-356.
	w	Vanaja, DK, et al, 2000, Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells, Cancer Research, Vol. 60, pp. 4714-4718.
	х	Manjili, MH, et al 2002, Immunotherapy of cancer using heat shock proteins, Frontiers in Bioscience, Vol. 7, pp. d43-52.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

5R 7/8/02 Notice of R ferences Cited

Notic of R ferences Cited

Application/Control No. 09/676,340	Applicant(s)/Patent Under Reexamination SUBJECK ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1642	Page 4 of 5

U.S. PATENT DOCUMENTS

	OICH ATEM DOCUMENTO					
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	Α	US-				
	В	US-				
	С	US-				
	٥	US-				
	Е	US-				
	F	US-				
	G	US-				
	Н	US-				
	1	US-				
	J	US-				
	Κ	US-				
	L	US-				
	М	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Z					
	0					
	Р					
	Ø					
	R					
	S					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)				
	U	Yedavelli, SPK, et al, 1999, Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model, International Journal of Molecular Medicine, Vol. 4, No. 3, pp. 243-248.				
	V	Udono, H, et al, 2001, Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock protein cognate protein 70, International Immunology, Vol. 13, No. 10, pp. 1233-1242.				
	w	Blachere, NE, et al, 1995, Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors, Seminars in Cancer Biology, Vol. 6, No. 6, pp. 349-355.				
	х	Menoret, A, et al, 1998, Heat-shock protein-based anticancer immunotherapy: an idea whose time has come, Seminars in Oncology, Vol. 25, No. 6, pp. 654-660.				

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

SR 7/8/02

Notice of References Cited

Notic of Referenc s Cited

Application/Control No.

O9/676,340

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under Reexamination SUBJECK ET AL.

Art Unit
Page 5 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	K	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Ρ					
	α					
	R					
	S					
	Т					

NON-PATENT DOCUMENTS

	_					
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)				
	U	Przepiorka, D, et al, 1998, Heat shock protein-peptide complexes as immunotherapy for human cancer, Molecular Medicine Today, Vol. 4, No. 11, pp. 478-484.				
	V					
	w					
	x					

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

7/8/02

Notice of References Cited